Vincerx Pharma, Inc. (VINC) 10-Year Financial Performance & Capital Metrics

VINC • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutVincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.Show more

Revenue $0
EBITDA -$31M +24.5%
Net Income -$30M +25.1%
EPS (Diluted) -5.75 +15.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -431.29% -216.2%
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 10.9% through buybacks
✓Trading at only 0.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-18.72%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM40.79%

EPS CAGR

10Y-

5Y-

3Y-

TTM123.29%

ROCE

10Y Avg-163.41%

5Y Avg-163.41%

3Y Avg-211.82%

Latest-410.32%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	173K	173K	340K	939K	915K	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	-173K	-173K	-340K	-939K	-915K	0
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	0%	-0.97%	-1.76%	0.03%	1%
Operating Expenses+	45K	10.71M	62.66M	71.11M	41.69M	31.46M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	45K	3.6M	22.57M	18.95M	13.64M	15.98M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	0	7.12M	40.08M	52.15M	28.06M	15.49M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0
Operating Income+	-45K	-10.71M	-62.66M	-68.72M	-42.61M	-31.46M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	-237.09%	-4.85%	-0.1%	0.38%	0.26%
EBITDA+	9K	-15.85M	-62.32M	-67.78M	-41.69M	-31.46M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	-1762.11%	-2.93%	-0.09%	0.38%	0.25%
D&A (Non-Cash Add-back)	54K	0	340K	939K	915K	0
EBIT	-45K	-15.85M	-39.31M	-62.98M	-40.16M	0
Net Interest Income+	54.27K	46.27K	0	664K	1.25M	472K
Interest Income	54.27K	54.27K	0	664K	1.25M	472K
Interest Expense	0	8K	0	0	0	0
Other Income/Expense	0	-5.91M	23.35M	5.74M	2.45M	1.39M
Pretax Income+	-45K	-16.62M	-39.31M	-62.98M	-40.16M	-30.07M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1.2%	1%	1%	1.04%	1%	1%
Net Income+	-54K	-16.62M	-39.31M	-65.37M	-40.16M	-30.07M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	-306.78%	-1.36%	-0.66%	0.39%	0.25%
Net Income (Continuing)	-45K	-16.62M	-39.31M	-62.98M	-40.16M	-30.07M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.03	-11.67	-8.30	-10.86	-6.84	-5.75
EPS Growth %	-	-370.66%	0.29%	-0.31%	0.37%	0.16%
EPS (Basic)	-0.03	-11.67	-8.30	-10.86	-6.84	-5.75
Diluted Shares Outstanding	1.43M	1.42M	4.74M	5.8M	5.87M	5.23M
Basic Shares Outstanding	1.43M	1.42M	4.74M	5.8M	5.87M	5.23M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	791.04K	63.11M	111.84M	55.96M	14.73M	6.41M
Cash & Short-Term Investments	684.71K	61.79M	111.46M	52.46M	12.78M	4.99M
Cash Only	684.71K	61.79M	111.46M	11.66M	12.78M	4.99M
Short-Term Investments	0	0	0	40.8M	0	0
Accounts Receivable	0	0	0	1.37M	1.04M	1.04M
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	106.33K	214K	200K	2M	856K	128K
Total Non-Current Assets+	1K	82K	5.83M	3.32M	3.48M	1.59M
Property, Plant & Equipment	0	0	4.18M	3.24M	2.33M	0
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	1K	65.69M	0	0	0	0
Other Non-Current Assets	0	-65.61M	1.65M	81K	1.16M	1.59M
Total Assets+	1K	63.19M	117.68M	59.29M	18.22M	8.01M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	63191%	0.86%	-0.5%	-0.69%	-0.56%
Total Current Liabilities+	44K	37.81M	13.92M	9.16M	5.61M	5.28M
Accounts Payable	35K	491K	2.02M	4.07M	2.5M	2.03M
Days Payables Outstanding	73.85	1.04K	2.17K	1.58K	996.07	-
Short-Term Debt	0	0	738K	1.02M	0	0
Deferred Revenue (Current)	0	0	1000K	0	0	0
Other Current Liabilities	9K	27.31M	994K	1.16M	191K	8K
Current Ratio	17.98x	1.67x	8.04x	6.11x	2.63x	1.21x
Quick Ratio	17.98x	1.67x	8.04x	6.11x	2.63x	1.21x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	3.3M	491K	3.44M	2.46M	1.39M	0
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	0	0	3.44M	2.41M	1.34M	0
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	50K	50K	0
Total Liabilities	44K	5.5M	17.36M	11.62M	7M	5.28M
Total Debt+	0	0	4.17M	3.44M	2.5M	0
Net Debt	-684.71K	-61.79M	-107.28M	-8.23M	-10.28M	-4.99M
Debt / Equity	-	-	0.04x	0.07x	0.22x	-
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-76.08x	-	-	-	-	-
Interest Coverage	-	-1339.25x	-	-	-	-
Total Equity+	-44K	57.69M	100.32M	47.67M	11.22M	2.72M
Equity Growth %	-	1312.07%	0.74%	-0.52%	-0.76%	-0.76%
Book Value per Share	-0.03	40.51	21.18	8.22	1.91	0.52
Total Shareholders' Equity	-44K	25.38M	100.32M	47.67M	11.22M	2.72M
Common Stock	1K	1K	2K	2K	2K	8K
Retained Earnings	-45K	-16.66M	-55.97M	-118.95M	-159.11M	-189.19M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	-1K	0	-21K	-26K	8K	119K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-35K	-2.28M	-33.4M	-59.6M	-40.45M	-26.13M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	-64.12%	-13.66%	-0.78%	0.32%	0.35%
Net Income	-54K	-10.38M	-39.31M	-65.37M	-40.16M	-30.07M
Depreciation & Amortization	0	20K	340K	939K	915K	1.09M
Stock-Based Compensation	1.2K	4.38M	23.31M	10.06M	3.56M	3.47M
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	7K	4.66M	-23.36M	-4.21M	-583K	-438K
Working Capital Changes	10.8K	-959K	5.61M	-1.02M	-4.19M	-178K
Change in Receivables	0	0	0	200K	328K	0
Change in Inventory	0	0	0	-200K	0	0
Change in Payables	35K	456K	1.53M	1.05M	-1.57M	-468K
Cash from Investing+	-65.64M	-65.64M	-5.26M	-40.58M	41.5M	212K
Capital Expenditures	0	0	-5.26M	0	0	0
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	-65.64M	-65.64M	0	0	0	0
Cash from Financing+	66.46M	64.07M	88.45M	280K	114K	17.99M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	66.46M	64.07M	41.02M	280K	114K	118K
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-35K	-2.28M	-38.66M	-59.6M	-40.45M	-26.13M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	-64.12%	-15.96%	-0.54%	0.32%	0.35%
FCF per Share	-0.02	-1.60	-8.16	-10.28	-6.89	-4.99
FCF Conversion (FCF/Net Income)	0.65x	0.14x	0.85x	0.91x	1.01x	0.87x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-57.67%	-49.75%	-88.34%	-136.38%	-431.29%
Return on Invested Capital (ROIC)	-	-	-	-317.4%	-158.27%	-
Debt / Equity	-	-	0.04x	0.07x	0.22x	-
Interest Coverage	-	-1339.25x	-	-	-	-
FCF Conversion	0.65x	0.14x	0.85x	0.91x	1.01x	0.87x

Frequently Asked Questions

Growth & Financials

Vincerx Pharma, Inc. (VINC) reported $1.1M in revenue for fiscal year 2024.

Vincerx Pharma, Inc. (VINC) grew revenue by 0.0% over the past year. Growth has been modest.

Vincerx Pharma, Inc. (VINC) reported a net loss of $22.6M for fiscal year 2024.

Dividend & Returns

Vincerx Pharma, Inc. (VINC) has a return on equity (ROE) of -431.3%. Negative ROE indicates the company is unprofitable.

Vincerx Pharma, Inc. (VINC) had negative free cash flow of $22.8M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener